Industrializing iPSC and Harnessing its Medical Applications – An Interview with Dr. Hong-Lin Su

by GeneOnline
Share To
Featured in the special topic of Gene and Cell Therapy, GeneOnline is honored to interview Professor Hong-Lin Su from the Department of Life Sciences at National Chung Hsing University, who is one of the few induced pluripotent stem cell (iPSC) experts in the field of cell therapy in Taiwan, with experience in academia, industry, and clinical practice.

The technology of neural differentiation from pluripotent stem cells developed by Prof. Su’s team not only won the National Innovation Award in 2017 but was also successfully patented in Taiwan, the US, and Japan. During the interview, Prof. Su introduced the principle of iPS cell therapy and its current clinical applications. He also shared his rich experience accelerating the formation of Taiwan's cell therapy industry chain by establishing DuoGenic Stem Cells in recent years.

It's free! Log in now to read

From Sweet to Risky: The Alarming Findings on Sucralose’s Genotoxicity
GHG Emissions as a ESG Metric
NSTC Joins Forces with Taiwan Biomedical Start-ups to Rise to the World Stage, Showcasing Innovations at US BIO’s Demo Day
Krystal Biotech’s First Topical Gene Therapy Approved by FDA
The Emergence of General AI for Medicine: Medical Applications of ChatGPT
Strengthening Genetic Screening Platform in APAC for Lung Cancer Precision Medicine: An Interview with Dr. Koichi Goto
2023 International Healthcare Week: Showcasing Emerging Competencies of Hong Kong’s Biomedical Industry
Scroll to Top